Target intelligence / Profile preview

Acetylcholine receptor subunit alpha (CHRNA)

Target
CHRNA
Molecular classification
Receptor, Ion channel (specifically, ligand-gated ion channel), Cys-loop receptor superfamily
01

Overview

The acetylcholine receptor α subunit is an integral membrane protein making up the principal agonist binding site of nicotinic acetylcholine receptors (nAChRs). Each nAChR is composed of five subunits, typically two α and three others, assembled into a ligand-gated ion channel. Binding of acetylcholine to sites formed by the α subunit and adjacent subunit triggers conformational changes that open the channel for cation influx, mediating rapid synaptic transmission. Multiple α subunit isoforms exist—CHRNA1 is fundamental to muscle nAChRs, while CHRNA2–CHRNA10 are important in neuronal nAChRs, conferring distinct pharmacological and physiological properties. The α subunit is a key therapeutic target in diseases affecting neuromuscular junctions and neural signaling, and is also the major antigen in autoimmune myasthenia gravis.

Other names
Nicotinic acetylcholine receptor alpha subunitnAChR α subunitCHRNA1CHRNA2etc. (denoting specific genes)Main immunogenic region (MIR, referring to an epitope within the subunit)
02

Mechanism of action

Channel agonists activate cation influx by binding at the α subunit interface, depolarizing the membrane. Channel antagonists block acetylcholine binding or channel opening, inhibiting signaling. Toxins (e.g., α-bungarotoxin) irreversibly bind the α subunit, blocking neurotransmission. Allosteric modulators alter receptor sensitivity and desensitization.

03

Biological functions

Signal transduction (initiates cation influx upon acetylcholine binding)Neuromuscular transmission (in muscle subtype; CHRNA1)Synaptic transmission (in neuronal subtypes)Modulation of neuronal excitability
04

Disease associations

Neurodegenerative disease (e.g., Alzheimer's disease, nicotine dependence)Neuromuscular disorders (e.g., myasthenia gravis; fetal and adult forms)Addiction (nicotine and other drugs targeting nAChRs)Inflammation (modulatory roles)Other (congenital myasthenic syndromes)
05

Safety considerations

Muscle paralysis (blockage or autoimmune attack, e.g., myasthenia gravis)Nicotine dependence, addiction (target for psychotropic drugs)Cardiac arrhythmias (off-target effects of channel modulators)Drug resistance and receptor desensitization
06

Interacting drugs

Acetylcholine

18 more in the full profile.

07

Biomarkers

Anti–acetylcholine receptor antibody (used in myasthenia gravis diagnosis)Expression levels (e.g., CHRNA1 for muscle AChR, CHRNA4 for neuronal)Receptor clustering/autoantigenicity (MIR region within α subunit)

Beyond the preview

Go deeper on Acetylcholine receptor subunit alpha (CHRNA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acetylcholine receptor subunit alpha (CHRNA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call